Marija Plodinec studied physics in Zagreb and received her doctorate in 2010 from the University of Basel. She co-founded ARTIDIS AG and in November 2017 became the CEO and a Member of the Board of Directors. In 2020 ARTIDIS AG opened its flagship US-based office in the heart of the world-renowned Texas Medical Center. For over twelve years, Marija has driven the development of ARTIDIS technology from basic research to the first clinical studies.
ARTIDIS medical device employs ARTIDIS’ patented nanosensor measurements to create a nanomechanical signature of cancer tissue. This signature can be correlated to which tumors are more likely to metastasize and enable clinicians to predict response to neoadjuvant therapy immediately after the first diagnostic biopsy is taken.
Dr. Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications.
Under her leadership, ARTIDIS fundraised more than 45M USD, successfully completed the large clinical study on 545 patients in Switzerland, grown to +60 FTE and partnered up with leading US pharmaceutical and clinical institutions.
